Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Chief Accounting Officer | October 01, 2026 | October 02, 2026 |
| PSYCHEMEDICS CORPPMD · Entity 85009 | VP - Finance | November 11, 2020 | November 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 420,000 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Purchase · Acquired 20,000 · Balance 420,000 F1: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
PSYCHEMEDICS CORP
Report date November 11, 2020 · Filed November 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.005 Par ValueSEC Table I · non-derivative | Direct | 25,866 |
Reported balance
After 2020-11-11 transaction · row 1
1 source rowRow 1 · 2020-11-11 · Grant · Acquired 10,000 · Balance 25,866 F1: Represents restricted stock units that are to be settled solely in shares of Common Stock. The units vest with respect to 25% of the shares on the first anniversary date of the grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient remains in the continuous employ of the Issuer through each such respective vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.07 · Expires 2030-11-11 | Direct | 3,000 |
Reported balance
After 2020-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-11 · Grant · Acquired 3,000 · Balance 3,000 F2: The option becomes exercisable with respect to 25% of the shares on the first anniversary date of grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient is in the continuous employ of the Issuer through each such respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are to be settled solely in shares of Common Stock. The units vest with respect to 25% of the shares on the first anniversary date of the grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient remains in the continuous employ of the Issuer through each such respective vesting date.
F2: The option becomes exercisable with respect to 25% of the shares on the first anniversary date of grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient is in the continuous employ of the Issuer through each such respective vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 16:00 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | PurchaseCommon Stock | 20,000 | $0.92 | $18,400.00 |
DisclosureSEC source: 0001171843-26-006349 · ownership.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,000 F1 · balance_after: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 12:01 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | PurchaseCommon Stock | 2,500 | $1.14 | $2,850.00 |
DisclosureSEC source: 0001171843-26-006235 · ownership.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F1 · balance_after: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 20:58 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantCommon Stock | 15,000 | $1.89 | $28,350.00 |
DisclosureSEC source: 0001171843-26-002834 · ownership.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,500 F1 · balance_after: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 20:00 UTC Amendment | Compass Therapeutics, Inc. CMPX · Entity 5614 | PurchaseCommon Stock | 15,000 | $1.89 | $28,350.00 |
DisclosureSEC source: 0001171843-26-002894 · ownership.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,500 F1 · balance_after: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 435,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001171843-26-000056 · ownership.xml · derivative · entry 2 Lerner Neil · CIK 0001505148 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,000 Underlying: Common Stock · 435,000 shares Expires 2036-01-02 F3 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantCommon Stock | 62,500 | $5.17 | $323,125.00 |
DisclosureSEC source: 0001171843-26-000056 · ownership.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,500 F1 · shares: Represents restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027. F2 · balance_after: 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 13:25 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | PurchaseCommon Stock | 20,000 | $1.42 | $28,400.00 |
DisclosureSEC source: 0001171843-25-002084 · ownership.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 F1 · price: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.43 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:11 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001171843-25-000829 · ownership.xml · derivative · entry 1 Lerner Neil · CIK 0001505148 · SVP, CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 11, 2025. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:38 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001505148-20-000026 · edgar.xml · derivative · entry 2 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock, $.005 Par Value · 3,000 shares Expires 2030-11-11 F2 · derivative.exercise_date: The option becomes exercisable with respect to 25% of the shares on the first anniversary date of grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient is in the continuous employ of the Issuer through each such respective vesting date. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:38 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | GrantCommon Stock, $.005 Par Value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001505148-20-000026 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,866 F1 · shares: Represents restricted stock units that are to be settled solely in shares of Common Stock. The units vest with respect to 25% of the shares on the first anniversary date of the grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient remains in the continuous employ of the Issuer through each such respective vesting date. Read SEC document |
| May 04, 2020 Filed May 6, 2020 19:21 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 399 | $5.75 | $2,294.25 |
DisclosureSEC source: 0001505148-20-000002 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,866 Read SEC document |
| May 03, 2019 Filed May 7, 2019 15:10 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 154 | $10.60 | $1,632.40 |
DisclosureSEC source: 0001373894-19-000038 · edgar.xml · nonDerivative · entry 2 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,265 Read SEC document |
| May 03, 2019 Filed May 7, 2019 15:10 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | GrantCommon Stock, $.005 Par Value | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001373894-19-000038 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,419 F1 · shares: Represents restricted stock units that are to be settled solely in shares of Common Stock. The units vest with respect to 25% of the shares on the first anniversary date of grant, and with respect to an additional 25% on each of the three anniversary dates thereafer, so long as the recipient remains in the continuous employ of the Issuer through each such respective vesting date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 15:37 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 301 | $11.60 | $3,491.60 |
DisclosureSEC source: 0001373894-19-000021 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,919 Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 15:48 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | SaleCommon Stock, $.005 Par Value | 1,412 | $15.06 | $21,264.72 |
DisclosureSEC source: 0001373894-19-000015 · edgar.xml · nonDerivative · entry 2 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,220 F2 · price: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.93 to $15.25, inclusive. The reporting person undertakes to provide Psychemedics Corporation, any security holder of Psychemedics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 15:48 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | SaleCommon Stock, $.005 Par Value | 7,645 | $15.11 | $115,515.95 |
DisclosureSEC source: 0001373894-19-000015 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,632 F1 · price: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.30, inclusive. The reporting person undertakes to provide Psychemedics Corporation, any security holder of Psychemedics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 22, 2018 Filed May 23, 2018 15:50 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | SaleCommon Stock, $.005 Par Value | 1,879 | $19.99 | $37,561.21 |
DisclosureSEC source: 0001739481-18-000025 · edgar.xml · nonDerivative · entry 2 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,277 F2 · price: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.96 to $20.00, inclusive. The reporting person undertakes to provide Psychemedics Corporation, any security holder of Psychemedics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 21, 2018 Filed May 23, 2018 15:50 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | SaleCommon Stock, $.005 Par Value | 3,013 | $20.14 | $60,681.82 |
DisclosureSEC source: 0001739481-18-000025 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,156 F1 · price: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.39, inclusive. The reporting person undertakes to provide Psychemedics Corporation, any security holder of Psychemedics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 08, 2018 Filed May 10, 2018 10:43 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 282 | $20.21 | $5,699.22 |
DisclosureSEC source: 0001739481-18-000022 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,169 Read SEC document |
| May 03, 2018 Filed May 7, 2018 15:45 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | GrantCommon Stock, $.005 Par Value | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001739481-18-000014 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,451 F1 · shares: Represents restricted stock units that are to be settled solely in shares of Common Stock. The units vest with respect to 25% of the shares on the first anniversary date of grant, and with respect to an additional 25% on each of the three anniversary dates thereafer, so long as the recipient remains in the continuous employ of the Issuer through each such respective vesting date. Read SEC document |
| April 30, 2018 Filed May 2, 2018 15:17 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 286 | $21.06 | $6,023.16 |
DisclosureSEC source: 0001033284-18-000049 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,451 Read SEC document |
| May 23, 2017 Filed May 25, 2017 15:30 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 276 | $21.04 | $5,807.04 |
DisclosureSEC source: 0001240679-17-000018 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,447 F1 · balance_after: Includes an Additional 81 Shares acquired since May 8, 2017 under the Company's Dividend Reinvestment Plan Read SEC document |
| May 08, 2017 Filed May 9, 2017 16:27 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 284 | $20.60 | $5,850.40 |
DisclosureSEC source: 0001505148-17-000018 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,642 F1 · balance_after: Includes an additional 515 shares acquired since September 10, 2015 under the Company's Dividend Reinvestment Plan. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:41 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $18.87 | $0.00 |
DisclosureSEC source: 0001505148-17-000011 · edgar.xml · derivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock, $.005 Par Value · 12,000 shares Expires 2027-05-04 F1 · derivative.exercise_date: The option becomes exercisable with respect to 25% of the shares on the first anniversary date of grant, and with respect to an additional 25% on each of the three anniversary dates thereafter, so long as the recipient remains in the continuous employ of the Issuer through each such respective vesting date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 15:27 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | Tax withholdingCommon Stock, $.005 Par Value | 311 | $18.56 | $5,772.16 |
DisclosureSEC source: 0001505148-17-000007 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,411 Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 15:32 UTC | PSYCHEMEDICS CORP PMD · Entity 85009 | SaleCommon Stock, $.005 Par Value | 3,000 | $24.75 | $74,250.00 |
DisclosureSEC source: 0001505148-16-000005 · edgar.xml · nonDerivative · entry 1 Lerner Neil · CIK 0001505148 · VP - Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,722 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.